De Novo Antibody Sequencing

Curia has developed proprietary methods to perform de novo antibody sequencing, a technique by which the amino acid sequence of an antibody is discovered without prior knowledge of the DNA or protein sequence. This differs from sequence confirmation by peptide mapping, a service where the protein sequence is already known and is used as a guideline to confirm the sequence. De novo antibody sequencing is a valuable tool for enabling recombinant production of a commercial antibody with useful properties, and is frequently faster than raising new antibodies from immunized sources.

Key Benefits

• Discover antibody’s sequence without prior knowledge
• 100% sequence coverage and more than 95% working sequence
• Produce antibody performs as well as or even better than the original one